References
- Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol 2010;9:1097–105.
- Sarma N. Hand, foot, and mouth disease: current scenario and Indian perspective. Indian J Dermatol Venereol Leprol 2013;79:165–75.
- Chen JF, Zhang RS, Ou XH, Chen FM, Sun BC. The role of enterovirus 71 and coxsackievirus A strains in a large outbreak of hand, foot, and mouth disease in 2012 in Changsha, China. Int J Infect Dis 2014;28C:17–25.
- Wang S, Liu C. Enterovirus 71: epidemiology, pathogenesis and management. Expert Rev Anti Infect Ther 2009;7: 735–42.
- HFMD specialists in Ministry of Health, EV71 enterovirus clinical specialist’s common view. Chinese Children medical magazine,2011;49:675–8.
- Fang Y, Wang S, Zhang L, Guo Z, Huang Z, Tu C, et al. Risk factors of severe hand, foot and mouth disease: a meta-analysis. Scand J Infect Dis 2014;46:515–22.
- Chinese Ministry of Health, HFMD diagnose and treatment index. International breathing magazine 2010;30:1473–75.
- Xiong XY Liu CF, Wang LJ, Li JJ, Xu W, Wen GF, et al. Characteristics of circulatory disturbance and the treatment of severe hand-foot-and-mouth disease. Clin J Pediatr 2012;50:435–9.
- Ho M, Chen E, Hsu K, Twu S, Chen K, Tsai S, et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 1999; 341:929–35.
- Zhang Y, Zhu Z, Yang W, Ren J, Tan X, Wang Y, et al. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol J 2010;7:94.
- Tsou Y-A, Cheng Y-K, Chung H-K, Yeh Y-C, Lin C-D, Tsai M-H, et al. Upper aerodigestive tract sequelae in severe enterovirus 71 infection: predictors and outcome. Int J Pediatr Otorhinolaryngol 2008;72:41–7.
- Benarroch EE. Brainstem respiratory control: substrates of respiratory failure of multiple system atrophy. Mov Disord 2007;22:155–61.
- Chang L-Y, Hsiung CA, Lu C-Y, Lin T-Y, Huang F-Y, Lai Y-H, et al. Status of cellular rather than humoral immunity is correlated with clinical outcome of enterovirus 71. Pediatr Res 2006;60:466–71.
- Lin Y-W, Chang K-C, Kao C-M, Chang S-P, Tung Y-Y, Chen S-H. Lymphocyte and antibody responses reduce enterovirus 71 lethality in mice by decreasing tissue viral loads. J Virol 2009;83:6477–83.
- Nagata N, Iwasaki T, Ami Y, Tano Y, Harashima A, Suzaki Y, et al. Differential localization of neurons susceptible to enterovirus 71 and poliovirus type 1 in the central nervous system of cynomolgus monkeys after intravenous inoculation. J Gen Virol 2004;85:2981–9.
- Xing W, Liao Q, Viboud C, Zhang J, Sun J, Wu JT, et al. Hand, foot, and mouth disease in China, 2008–12: an epidemiological study. Lancet Infect Dis 2014;14:308–18.
- Durbin CG, Blanch L, Fan E, Hess DR. Respiratory Care year in review 2013: airway management, noninvasive monitoring, and invasive mechanical ventilation. Respir Care 2014;59:595–606.
- Davidson NC, Struthers AD. Brain natriuretic peptide. J Hypertens 1994;12:329–36.
- Cantinotti M, Law Y, Vittorini S, Crocetti M, Marco M, Murzi B, et al. The potential and limitations of plasma BNP measurement in the diagnosis, prognosis, and management of children with heart failure due to congenital cardiac disease: an update. Heart Fail Rev 2014:19:727–42.
- Cowie MR. BNP-guided therapy for chronic heart failure: anything more than just an attractive concept? Eur Heart J 2014;ehu134.
- McDonagh T, Robb S, Murdoch D, Morton J, Ford I, Morrison C, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9–13.